Myasthenia gravis: Historical achievements and the “golden age” of clinical trials
作者: Tam M. Nguyen-CaoDeborah GelinasRhonda GriffinElsa Mondou
作者单位: 1Scientific and Medical Affairs, Grifols, 79 TW Alexander Drive 4101 Research Commons, Research Triangle Park, NC 27709, USA
2Grifols Bioscience Research Group, Grifols, 79 TW Alexander Drive 4201 Research Commons, Research Triangle Park, NC 27709, USA
刊名: Journal of the Neurological Sciences, 2019, Vol.406
来源数据库: Elsevier Journal
DOI: 10.1016/j.jns.2019.116428
关键词: Acetylcholine receptor antibodiesAutoantibodyClinical trialComplement-inhibitionCorticosteroidsFcRn antibodiesImmunoglobulinMyasthenia gravisPlasma exchangeThymectomy
英文摘要: Abstract(#br)Since the death of Chief Opechankanough >350 years ago, the myasthenia gravis (MG) community has gained extensive knowledge about MG and how to treat it. This review highlights key milestones in the history of treatment and discusses the current “golden age” of clinical trials. Although originally thought by many clinicians to be a disorder of hysteria and fluctuating weakness without observable cause, MG is one the most understood autoimmune neurologic disorders. However, studying it in clinical trials has been challenging due to the fluctuating nature of the medical condition which impacts MG clinical outcomes. Clinical trials must also account for the possibility of a placebo effect. Because MG is a rare incurable autoimmune disorder, it limits the number of potential...
全文获取路径: Elsevier  (合作)
影响因子:2.243 (2012)

  • gravis 重的
  • golden age 黄金时代
  • receptor 接受体
  • inhibition 抑制
  • clinical 临床的
  • trial 试验
  • exchange 交换